PURPOSE: Traditional treatment for @entity1149 ( @entity1149 ), radiation plus surgery, yields a 50% rate of complete resection and a 30% 5-year survival. On the basis of improved outcomes in other subsets of @entity5 , this trial tested the feasibility of induction chemoradiotherapy for @entity1149 . @entity1 AND METHODS: @entity1 with T3-4, N0-1 @entity1149 received two cycles of @entity900 and @entity2879 concurrently with radiation (45 Gy). @entity1 with stable or responding disease underwent thoracotomy. All @entity1 received two more cycles of chemotherapy. Survival was calculated by the Kaplan-Meier method and prognostic factors were assessed by Cox regression analysis. RESULTS: From April 1995 to November 1999, 110 eligible @entity1 (76 @entity1 , 34 @entity1 ) were entered onto the study (78 T3, 32 T4 @entity5 ). Induction therapy was completed by 104 (95%) @entity1 . Of 95 @entity1 eligible for surgery, 88 (80%) underwent thoracotomy, two (1.8%) died postoperatively, and 83 (76%) had complete resection. Pathologic complete response (CR) or minimal microscopic disease was seen in 61 (56%) resection specimens. Five-year survival was 44% for all @entity1 and 54% after complete resection, with no difference between T3 and T4 @entity5 . Pathologic CR led to better survival than when any @entity66 was present (P = .02). Disease progression occurred mainly in distant sites. CONCLUSION: This combined-modality approach is feasible and is associated with high rates of complete resection and pathologic CR in both T3 and T4 @entity5 . Local control and overall survival seem markedly improved relative to previous studies of radiation plus resection.

Induction chemoradiation and surgical resection for superior sulcus XXXX : long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'PATIENTS', 'men'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III NSCLC', 'tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['SS NSCLC', 'superior sulcus non-small-cell lung cancers'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung carcinomas']
